HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,440 | +8.7% | 37,696 | +2.6% | 0.01% | +11.1% |
| Q2 2023 | $1,325 | -16.7% | 36,738 | -11.8% | 0.01% | -18.2% |
| Q1 2023 | $1,591 | -33.3% | 41,654 | -0.6% | 0.01% | -35.3% |
| Q4 2022 | $2,385 | -99.9% | 41,908 | -7.6% | 0.02% | +30.8% |
| Q3 2022 | $1,794,000 | +86.1% | 45,370 | +107.0% | 0.01% | +116.7% |
| Q2 2022 | $964,000 | -12.6% | 21,920 | -20.8% | 0.01% | 0.0% |
| Q1 2022 | $1,103,000 | +4.9% | 27,665 | +5.8% | 0.01% | +20.0% |
| Q4 2021 | $1,051,000 | +19.2% | 26,145 | +20.6% | 0.01% | 0.0% |
| Q3 2021 | $882,000 | +13.7% | 21,677 | +26.8% | 0.01% | +25.0% |
| Q2 2021 | $776,000 | +27.6% | 17,097 | +17.2% | 0.00% | +33.3% |
| Q1 2021 | $608,000 | +19.2% | 14,582 | +22.1% | 0.00% | 0.0% |
| Q4 2020 | $510,000 | +84.1% | 11,939 | -21.8% | 0.00% | +50.0% |
| Q3 2018 | $277,000 | -37.2% | 15,258 | -41.6% | 0.00% | -33.3% |
| Q2 2018 | $441,000 | -20.7% | 26,114 | -8.0% | 0.00% | -25.0% |
| Q1 2018 | $556,000 | -37.2% | 28,395 | -35.0% | 0.00% | -33.3% |
| Q4 2017 | $885,000 | +391.7% | 43,682 | +321.0% | 0.01% | +500.0% |
| Q3 2017 | $180,000 | +39.5% | 10,375 | +2.8% | 0.00% | 0.0% |
| Q2 2017 | $129,000 | -9.8% | 10,094 | -14.5% | 0.00% | 0.0% |
| Q3 2016 | $143,000 | +8.3% | 11,808 | -22.7% | 0.00% | 0.0% |
| Q2 2016 | $132,000 | +3.9% | 15,269 | +13.7% | 0.00% | 0.0% |
| Q1 2016 | $127,000 | -27.0% | 13,427 | +33.4% | 0.00% | 0.0% |
| Q4 2015 | $174,000 | -2.2% | 10,063 | -24.1% | 0.00% | 0.0% |
| Q3 2015 | $178,000 | +89.4% | 13,265 | +219.5% | 0.00% | 0.0% |
| Q2 2015 | $94,000 | +104.3% | 4,152 | +28.5% | 0.00% | – |
| Q1 2015 | $46,000 | +48.4% | 3,230 | +0.1% | 0.00% | – |
| Q4 2014 | $31,000 | -11.4% | 3,226 | -15.9% | 0.00% | – |
| Q3 2014 | $35,000 | -7.9% | 3,835 | 0.0% | 0.00% | – |
| Q2 2014 | $38,000 | -29.6% | 3,835 | -9.4% | 0.00% | – |
| Q1 2014 | $54,000 | +5.9% | 4,232 | +25.1% | 0.00% | – |
| Q4 2013 | $51,000 | -54.9% | 3,383 | -66.9% | 0.00% | -100.0% |
| Q3 2013 | $113,000 | +130.6% | 10,220 | +65.8% | 0.00% | – |
| Q2 2013 | $49,000 | – | 6,163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |